Epizyme stock: buy or sell?
December 6th, 2019
Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the United States.
Should I buy Epizyme stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to choose your own trading strategy that fits your character as inversor. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Check the only buy setup that matches with Epizyme stock now:
|New all-time high||No|
|New 52 week high||Yes|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Epizyme stock a buy?
Financial institutions and banks publish stock ratings everyday.At Stocks2.com, we gathered 5 ratings published for EPZM stock in the last 30 days. The general sentiment of these ratings is bullish for EPZM stock, with 5 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
Epizyme stock analysis
Shares of Epizyme closed on December 6th at $18.22 and rocketed an amazing 19.08%.
Epizyme rocketed an amazing 19.08% and closed at $18.22. Since last November 4th when EPZM stock price broke up the SMA200d line, it gained $6.37 (53.76%). EPZM shows a sign of strength in the short-term after finally breaking out above $17.00 on Nov/25 and marking a new rising bottom.
Epizyme shares rocketed 10.29% this week, ending at $18.22. Counting this, it's been 5 climbing weeks in a row, soaring a 60.09%.
This week, SMA20w and SMA40w crossed up triggering a rise of 10.29%. Since early November when EPZM stock price broke up the SMA40w line, it gained $6.37 (53.76%).
Epizyme stock price history
Epizyme IPO was on May 31st, 2013 at $20.00 per share1. Since then, EPZM stock sliced a -8.90%, with a yearly average of -1.50%.
1: Adjusted price after possible price splits or reverse-splits.
Epizyme stock historical price chart
EPZM stock reached 52-week highs on December/6 at $18.39, and all-time highs 2013-07-17 with a price of 45.72.
Epizyme stock price target is $20.50How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last 30 days we found 4 price forecasts for EPZM stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-6-24||HC Wainwright||Set Price Target||n/a||$25.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareEpizyme failed experts on February when it published an Earnings per Share (EPS) of $-0.29 when the analysts' forecast was $-0.49.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Epizyme annual sales rocketed an extraordinary 117.00% to $21.70 M USD from $10.00 marked in 2017. In line, its income margin (compared to revenues) boosted to -569.72%, that is $-123.63 million.
|2013||$68 M||-||$-3.48 M-5.1%||-|
|2014||$41 M||-39.53%||$-55.01 M-132.8%||1,480.60%|
|2015||$2.56 M||-93.82%||$-132.38 M-5170.9%||140.66%|
|2016||$8.01 M||212.77%||$-110.21 M-1376.4%||-16.74%|
|2017||$10 M||24.89%||$-134.31 M-1343.1%||21.86%|
|2018||$22 M||117.00%||$-123.63 M-569.7%||-7.95%|
Quarterly financial resultsEpizyme reported $9.70 million in sales for 2018-Q4, a inf% improvement compared to previous quarter. Reported quarter earnings marked $-22.95 M with a profit margin of -236.55%. Profit margin remained steady a 0.00% compared to previous quarter when profit margin was inf%. When comparing sales to same quarter last year, Epizyme sales marked an exceptional increase and climbed a inf%.
|2017-Q2||$10 M||-||$-28.02 M-280.2%||-|
|2018-Q2||$12 M||20.00%||$-29.13 M-242.7%||3.95%|
|2018-Q4||$10 M||-19.17%||$-22.95 M-236.5%||-21.23%|
Epizyme ownershipWhen you are planning to invest in shares of a company, it's always worth to overview its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Epizyme, 4.94% of all outstanding shares are owned by its staff.
Bearish positions for EPZM stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Epizyme:
|Market cap||$1.7 B||$151.3 B||$15.9 M||$113.3 B||$210.8 B|
|Total shares||91.1 M||1,770.0 M||19.7 M||2,490.0 M||2,290.0 M|
|Float shares||76.0 M||1,760.0 M||14.4 M||2,450.0 M||2,130.0 M|
|- Institutional holdings (%)||93.2%||76.5%||8.1%||11.0%||11.7%|
|- Insider holdings (%)||4.9%||0.7%||16.9%||0.0%||0.0%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, December 6th, 2019|
|Day range||$16.31 - $18.39|
|Average true range||$0.83|
|50d mov avg||$12.99|
|100d mov avg||$12.76|
|200d mov avg||$12.78|
Epizyme performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. For Epizyme, the comparison is made against , Dare Bioscience, GlaxoSmithKline, Novartis and Seattle Genetics.